A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy
2022-06-28
عنوان الدراسة
A Randomized Study of the Effect of Maintenance Therapy With Bevacizumab + Capecitabine Versus Bevacizumab Alone on Progression-free Survival in Patients With HER2-negative Metastatic Breast Cancer That Has Not Progressed During First-line Docetaxel Plus Bevacizumab Therapy
داعم الدراسة
Roche
دواء الدراسة
Bevacizumab+ Capecitabine
رقم بروتوكول الدراسة
MO22223
حالة الدراسة
Terminated
موقع الدراسة
KAH & OC
مرحلة الدراسة
3
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。